A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: ABBV-444
DRUG: REFRESH OPTIVE UD

Sponsor

AbbVie